Related Experiment Videos
Drug repositioning: identifying and developing new uses for existing drugs
1Dynogen Pharmaceuticals, Inc., 31 St James Avenue, Suite 905, Boston, Massachusetts 02116, USA. tashburn@dynogen.com
Nature Reviews. Drug Discovery
|August 3, 2004
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Rapid-Onset, Short-Duration Induction of Colorectal Contractions in Anesthetized, Adult, Male Rats.
The Journal of pharmacology and experimental therapeutics·2024
Recent Developments in On-Demand Voiding Therapies.
The Journal of pharmacology and experimental therapeutics·2024
Colorectal and bladder prokinetic activity of [Lys5, MeLeu9, Nle10]-NKA(4-10) after intranasal or sublingual delivery in dogs.
Canadian journal of physiology and pharmacology·2023
Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer.
Nature communications·2022
Artificial intelligence in drug discovery - what it is, where we stand and the path forward.
Nature reviews. Drug discovery·2026
Targeting T follicular helper cells for lifelong health.
Nature reviews. Drug discovery·2026
Design, simulate, refine: simulation-guided clinical trials for accelerated drug development.
Nature reviews. Drug discovery·2026
Three-Dimensional Descriptions of π/π, CH/π, and Halogen/π Interactions Formed between Phenyl Substructures.
The journal of physical chemistry. B·2026
Fast activity prediction of chemically modified siRNAs via structure-based energy calculations and inference-augmented tabular deep learning.
Molecular therapy. Nucleic acids·2026
Bicyclo[1.1.1]pentane as a Phenyl Isosteric Replacement.
ACS medicinal chemistry letters·2026
Conformationally constrained 6‑aryl‑1‑(3,4,5‑trimethoxyphenyl)-1H-pyrazolo[3,4‑b]pyrazines as novel microtubule destabilizers: design, synthesis, and antitumor evaluation.
Journal of enzyme inhibition and medicinal chemistry·2026
Structure- and Ligand-Based Discovery of Novel Non-Arginine-Based DDAH1 Inhibitors with Anti-Triple-Negative Breast Cancer Activity.
ACS medicinal chemistry letters·2026